PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33288659-0	2021	ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma.	lenvatinib	39-49	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	0-7	
33288659-14	2021	Among serum ST6GAL1-high HCC patients who underwent TKI therapy, lenvatinib therapy showed significantly better survival than sorafenib.	lenvatinib	65-75	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	Homo sapiens	12-19